OptimizeRx Corporation provided earnings guidance for the first quarter of 2024, for the quarter, the company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $19.2 million with a GAAP net loss between $8.2 million - $7.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11 USD | -1.08% | -1.08% | -23.13% |
Jun. 05 | Transcript : OptimizeRx Corporation - Shareholder/Analyst Call | |
May. 14 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.13% | 201M | |
+29.36% | 449B | |
+37.48% | 288B | |
+7.22% | 92.67B | |
+25.68% | 89.12B | |
+66.58% | 62.08B | |
+13.31% | 45.82B | |
+19.47% | 35.53B | |
-15.40% | 30.2B | |
+17.47% | 29.72B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Provides Earnings Guidance for the First Quarter of 2024